ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 996,28
0,49%
Dow Jones
38 706,49
0,08%
DAX
18 163,68
0,94%
Brent Oil
83,33
0,25%
Bitcoin
63 427,94
-0,89%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Acadia Pharmaceuticals Inc (ACAD)

  7. Acadia Pharmaceuticals Inc (ACAD) Actualités

ACAD

Acadia Pharmaceuticals (ACAD)

Acadia Pharmaceuticals Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:ACAD
DateHeureSourceTitreSymboleSociété
29/04/202422h16Business WireAcadia Pharmaceuticals is Proud to Announce the Winners of the Inaugural Rett Sibling ScholarshipNASDAQ:ACADAcadia Pharmaceuticals Inc
24/04/202422h05Business WireAcadia Pharmaceuticals to Announce First Quarter Financial Results on May 8, 2024NASDAQ:ACADAcadia Pharmaceuticals Inc
22/04/202415h04Business WireAcadia Pharmaceuticals annonce que la présentation de drogue nouvelle pour la trofinetide dans le traitement du syndrome de Rett a été acceptée pour dépôt et évaluation prioritaire par Santé CanadaNASDAQ:ACADAcadia Pharmaceuticals Inc
22/04/202415h04Business WireAcadia Pharmaceuticals Announces Trofinetide New Drug Submission for Treatment of Rett Syndrome Has Been Accepted for Filing and Priority Review by Health CanadaNASDAQ:ACADAcadia Pharmaceuticals Inc
19/04/202422h05Business WireAcadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ACADAcadia Pharmaceuticals Inc
17/04/202422h05Business WireAcadia Pharmaceuticals Presents New DAYBUE™ (trofinetide) Clinical Data at the 2024 American Academy of Neurology (AAN) Annual MeetingNASDAQ:ACADAcadia Pharmaceuticals Inc
02/04/202422h05Business WireAcadia Appoints Elizabeth H. Z. Thompson, Ph.D. as Executive Vice President, Head of Research and DevelopmentNASDAQ:ACADAcadia Pharmaceuticals Inc
01/04/202422h05Business WireAcadia Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare ConferenceNASDAQ:ACADAcadia Pharmaceuticals Inc
13/03/202421h05Business WireAcadia Pharmaceuticals to Participate in the UBS Virtual CNS DayNASDAQ:ACADAcadia Pharmaceuticals Inc
12/03/202412h21IH Market NewsOracle Soars 13% With Exceptional Growth and Boosts Nvidia Shares With Collaboration Announcement, and MoreNASDAQ:ACADAcadia Pharmaceuticals Inc
11/03/202421h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACADAcadia Pharmaceuticals Inc
11/03/202421h05Business WireAcadia Pharmaceuticals Announces Top-Line Results from Phase 3 ADVANCE-2 Trial of Pimavanserin in Negative Symptoms of SchizophreniaNASDAQ:ACADAcadia Pharmaceuticals Inc
29/02/202415h05Business WireAcadia Pharmaceuticals to Participate in TD Cowen’s 44th Annual Health Care Conference on March 6, 2024NASDAQ:ACADAcadia Pharmaceuticals Inc
28/02/202400h13Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACADAcadia Pharmaceuticals Inc
27/02/202422h05Business WireAcadia Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operating OverviewNASDAQ:ACADAcadia Pharmaceuticals Inc
14/02/202413h08Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:ACADAcadia Pharmaceuticals Inc
13/02/202422h05Business WireAcadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024NASDAQ:ACADAcadia Pharmaceuticals Inc
08/02/202423h05Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ACADAcadia Pharmaceuticals Inc
31/01/202402h48Business WireAcadia Announces Additions to Executive TeamNASDAQ:ACADAcadia Pharmaceuticals Inc
26/01/202423h25Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ACADAcadia Pharmaceuticals Inc
18/01/202422h05Business WireAcadia Announces the Passing of Former President Srdjan (Serge) StankovicNASDAQ:ACADAcadia Pharmaceuticals Inc
21/12/202322h05Business WireAcadia Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024NASDAQ:ACADAcadia Pharmaceuticals Inc
15/12/202318h46Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ACADAcadia Pharmaceuticals Inc
14/12/202311h59IH Market NewsApple Stocks Reach Record, Adobe Faces Stock Drops, Berkshire Hathaway Increases Stake in OXY, and MoreNASDAQ:ACADAcadia Pharmaceuticals Inc
14/12/202303h24Business WireDelaware District Court Rules in Favor of Acadia on Formulation Patent Construction (Markman) Claims Regarding NUPLAZID® (pimavanserin)NASDAQ:ACADAcadia Pharmaceuticals Inc
13/12/202319h41Business WireDelaware Federal District Court Rules in Favor of Acadia Pharmaceuticals in NUPLAZID® (pimavanserin) Patent LitigationNASDAQ:ACADAcadia Pharmaceuticals Inc
30/11/202315h05Business WireAcadia Pharmaceuticals Initiates Pivotal Phase 3 Study of Carbetocin (ACP-101) for the Treatment of Hyperphagia in Prader-Willi SyndromeNASDAQ:ACADAcadia Pharmaceuticals Inc
27/11/202315h05Business WireAcadia Pharmaceuticals Initiates Phase 2 Clinical Trial of ACP-204 for the Treatment of Alzheimer’s Disease PsychosisNASDAQ:ACADAcadia Pharmaceuticals Inc
21/11/202323h00Business WireAcadia Pharmaceuticals Announces Change in Research and Development LeadershipNASDAQ:ACADAcadia Pharmaceuticals Inc
02/11/202321h05Business WireAcadia Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operating OverviewNASDAQ:ACADAcadia Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:ACAD

Dernières Valeurs Consultées

SPI
SP500
S&P 500
FTSE
UKX
FTSE 100
NASDAQ
GOOGL
Alphabet
EU
VK
Vallourec
NASDAQ
AMZN
Amazon.com
EU
PX1
CAC 40
EU
AI
Air Liquide
EU
BEL20
Bel 20
EU
CS
Axa
EU
PX4
SBF 120
EU
BNP
BNP Paribas
NYSE
MRK
Merck
NASDAQ
AAPL
Apple
EU
RI
Pernod Ricard
EU
RNO
Renault
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés